Physician profile
Rose M Ray
NPI 1699958884
$3,959.86
in general payments reported to CMS, 2019-2025
26 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $1,162 · 2023: $1,331 · 2024: $462 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,239.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,143.72 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.57 | 2021-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $341.37 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Regeneron Healthcare Solutions, INC. | $182.63 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $145.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.92 | 2021-2023 | Entyvio |
| Genzyme Corporation | $62.26 | 2022-2025 | |
| Astellas Pharma US INC | $56.11 | 2021 | |
| Celgene Corporation | $54.32 | 2021-2024 | Zeposia |
| Myriad Genetic Laboratories, INC. | $51.90 | 2021 | |
| Intercept Pharmaceuticals, INC. | $43.50 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $24.63 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $21.69 | 2021 | |
| Fresenius Kabi USA, LLC | $20.90 | 2024 | Idacio |
| Boston Scientific Corporation | $19.93 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $19.10 | 2021 | |
| Myovant Sciences INC. | $17.74 | 2021 | |
| Qol Medical, LLC | $17.62 | 2022 | |
| Braintree Laboratories, INC. | $17.54 | 2022 | |
| Evoke Pharma, INC. | $16.27 | 2022 | |
| Merck Sharp & Dohme LLC | $15.32 | 2022 | |
| Redhill Biopharma INC. | $15.14 | 2022 | |
| Pfizer INC. | $14.90 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.57 | 2023 | |
| Antares Pharma, INC. | $13.29 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.